Recently approved PMSA-targeted radiotracer can pinpoint biochemical recurrent prostate cancer in men with unhelpful standard imaging.

Patients with mild cognitive impairment who take lipophilic statins have a more than doubled risk of progressing to dementia.

Tested so far in animal models, this tracer could further the development of treatments for this life-threatening disease for which there are currently no therapies.

New therapy uses light from decaying radiopharmaceuticals to attack cancer cells from inside the body.

Using an external tracking device can lead to super-resolution that can potentially improve neurological disorder detection.

Use enables direct imaging of disease process.

Using advanced artificial intelligence can give patients a personalized assessment of their risk for significant events, such as heart attack or death.

Images reveal older adults with above-average cognitive abilities have a resistance to tau and amyloid proteins.

Using 18F-DCPyL PSMA PET/CT can pinpoint more cancers in men who have biochemical failure with initial treatment.

Using PET/MRI 18F NaF offers new functional measure for assessing degeneration of knee joints.

18F-FDG PET/MRI can identify pain generator locations, leading to changes in pain management.

Cardiac imaging with PET and MRI shows excellent diagnostic accuracy compared with SPECT-MPI.

Imaging visualizes rheumatoid arthritis inflammation in preclinical study.

PET finds hypometabolism in healthy brains that may indicate pre-Alzheimer’s disease.

PET imaging aids researchers in search for anti-nicotine vaccine, but shows there is still a lot of work to do.

SPECT/MR debuted this week at the SNMMI annual meeting as a new preclinical hybrid molecular imaging system with promises of higher resolution and lower dose.